These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 24989947)

  • 1. Mechanisms of P-glycoprotein alteration during anticancer treatment: role in the pharmacokinetic and pharmacological effects of various substrate drugs.
    Kobori T; Harada S; Nakamoto K; Tokuyama S
    J Pharmacol Sci; 2014; 125(3):242-54. PubMed ID: 24989947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Co-formulation of P-glycoprotein Substrate and Inhibitor in Nanocarriers: An Emerging Strategy for Cancer Chemotherapy.
    Saneja A; Dubey RD; Alam N; Khare V; Gupta PN
    Curr Cancer Drug Targets; 2014; 14(5):419-33. PubMed ID: 24720364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of expression/function of intestinal P-glycoprotein under disease states.
    Murakami T; Bodor E; Bodor N
    Expert Opin Drug Metab Toxicol; 2020 Jan; 16(1):59-78. PubMed ID: 31821048
    [No Abstract]   [Full Text] [Related]  

  • 4. The contribution of P-glycoprotein to pharmacokinetic drug-drug interactions.
    Yu DK
    J Clin Pharmacol; 1999 Dec; 39(12):1203-11. PubMed ID: 10586385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional alterations of intestinal P-glycoprotein under diabetic conditions.
    Kobori T; Harada S; Nakamoto K; Tokuyama S
    Biol Pharm Bull; 2013; 36(9):1381-90. PubMed ID: 23995645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. P-glycoprotein inhibition: the past, the present and the future.
    Darby RA; Callaghan R; McMahon RM
    Curr Drug Metab; 2011 Oct; 12(8):722-31. PubMed ID: 21434857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in P-glycoprotein-based approaches for delivering anticancer drugs: pharmacokinetic perspective and clinical relevance.
    Saneja A; Khare V; Alam N; Dubey RD; Gupta PN
    Expert Opin Drug Deliv; 2014 Jan; 11(1):121-38. PubMed ID: 24295039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are the major effects of P-glycoprotein modulators due to altered pharmacokinetics of anticancer drugs?
    Relling MV
    Ther Drug Monit; 1996 Aug; 18(4):350-6. PubMed ID: 8857549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug-Drug Interactions of P-gp Substrates Unrelated to CYP Metabolism.
    Akamine Y; Yasui-Furukori N; Uno T
    Curr Drug Metab; 2019; 20(2):124-129. PubMed ID: 30280663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition.
    Zhou SF
    Xenobiotica; 2008 Jul; 38(7-8):802-32. PubMed ID: 18668431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of drug interactions with P-glycoprotein in drug discovery: in vitro assessment of the potential for drug-drug interactions with P-glycoprotein.
    Hochman JH; Yamazaki M; Ohe T; Lin JH
    Curr Drug Metab; 2002 Jun; 3(3):257-73. PubMed ID: 12083320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Altered intestinal P-glycoprotein expression levels affect pharmacodynamics under diabetic condition].
    Nawa A; Fujita-Hamabe W; Kisioka S; Tokuyama S
    Yakugaku Zasshi; 2012; 132(2):161-6. PubMed ID: 22293693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The influence of expression of P-glycoprotein on the penetration of anticancer drugs through multicellular layers.
    Tunggal JK; Melo T; Ballinger JR; Tannock IF
    Int J Cancer; 2000 Apr; 86(1):101-7. PubMed ID: 10728602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Individual and combined roles of CYP3A, P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) in the pharmacokinetics of docetaxel.
    van Waterschoot RA; Lagas JS; Wagenaar E; Rosing H; Beijnen JH; Schinkel AH
    Int J Cancer; 2010 Dec; 127(12):2959-64. PubMed ID: 21351274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overlapping ligand specificity of P-glycoprotein and serum alpha(1)-acid glycoprotein: evidences and potential implications.
    Zsila F
    Curr Drug Metab; 2007 Aug; 8(6):563-93. PubMed ID: 17691918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. P-glycoprotein-mediated efflux as a major factor in the variance of absorption and distribution of drugs: modulation of chemotherapy resistance.
    Johnson WW
    Methods Find Exp Clin Pharmacol; 2002 Oct; 24(8):501-14. PubMed ID: 12500430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The coordinated role of CYP450 enzymes and P-gp in determining cancer resistance to chemotherapy.
    Azzariti A; Porcelli L; Quatrale AE; Silvestris N; Paradiso A
    Curr Drug Metab; 2011 Oct; 12(8):713-21. PubMed ID: 21434858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simotinib as a modulator of P-glycoprotein: substrate, inhibitor, or inducer?
    Huang L; Shen C; Chen Y; Yan H; Cheng Z; Zhu Q
    Anticancer Drugs; 2016 Apr; 27(4):300-11. PubMed ID: 26766493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of oral bioavailability of anticancer drugs: from mouse to man.
    Schellens JH; Malingré MM; Kruijtzer CM; Bardelmeijer HA; van Tellingen O; Schinkel AH; Beijnen JH
    Eur J Pharm Sci; 2000 Dec; 12(2):103-10. PubMed ID: 11102737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. P-glycoprotein-mediated efflux transport of anticancer drugs at the blood-brain barrier.
    Tsuji A
    Ther Drug Monit; 1998 Oct; 20(5):588-90. PubMed ID: 9780140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.